ABVC Current Deferred Revenue vs Total Current Liabilities Analysis
ABVC Stock | USD 1.06 0.02 1.85% |
ABVC Biopharma financial indicator trend analysis is way more than just evaluating ABVC Biopharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ABVC Biopharma is a good investment. Please check the relationship between ABVC Biopharma Current Deferred Revenue and its Total Current Liabilities accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.
Current Deferred Revenue vs Total Current Liabilities
Current Deferred Revenue vs Total Current Liabilities Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ABVC Biopharma Current Deferred Revenue account and Total Current Liabilities. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between ABVC Biopharma's Current Deferred Revenue and Total Current Liabilities is 0.48. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of ABVC Biopharma, assuming nothing else is changed. The correlation between historical values of ABVC Biopharma's Current Deferred Revenue and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of ABVC Biopharma are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Current Deferred Revenue i.e., ABVC Biopharma's Current Deferred Revenue and Total Current Liabilities go up and down completely randomly.
Correlation Coefficient | 0.48 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Total Current Liabilities
Total Current Liabilities is an item on ABVC Biopharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of ABVC Biopharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from ABVC Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ABVC Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.As of May 17, 2024, Selling General Administrative is expected to decline to about 5 M. In addition to that, Tax Provision is expected to decline to about 217.9 K
2021 | 2022 | 2023 | 2024 (projected) | Other Operating Expenses | 11.7M | 16.1M | 8.4M | 4.2M | Total Revenue | 355.8K | 969.8K | 152.4K | 157.4K |
ABVC Biopharma fundamental ratios Correlations
Click cells to compare fundamentals
ABVC Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ABVC Biopharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 6.9M | 11.6M | 13.7M | 9.9M | 14.9M | 15.7M | |
Short Long Term Debt Total | 4.6M | 6.5M | 3.1M | 3.1M | 2.5M | 1.9M | |
Total Current Liabilities | 6.8M | 4.8M | 3.7M | 5.8M | 5.9M | 6.2M | |
Total Stockholder Equity | (151.0K) | 3.4M | 8.8M | 3.1M | 8.8M | 9.3M | |
Net Debt | 4.4M | 2.2M | (2.7M) | 3.0M | 1.7M | 1.8M | |
Retained Earnings | (15.9M) | (25.6M) | (38.5M) | (54.9M) | (65.4M) | (62.1M) | |
Common Stock Shares Outstanding | 1.7M | 2.0M | 2.5M | 3.2M | 4.3M | 4.6M | |
Liabilities And Stockholders Equity | 6.9M | 11.6M | 13.7M | 9.9M | 14.9M | 15.7M | |
Non Current Liabilities Total | 238.4K | 4.1M | 1.1M | 420.2K | 429.1K | 407.7K | |
Inventory | (477.0K) | (839.7K) | 26.0K | 1.3M | 1.5M | 1.6M | |
Other Stockholder Equity | 15.0M | 28.5M | 46.8M | 57.5M | 73.7M | 77.4M | |
Total Liab | 7.1M | 8.9M | 4.8M | 6.2M | 6.4M | 6.7M | |
Total Current Assets | 878.2K | 6.2M | 9.6M | 3.0M | 1.7M | 1.4M | |
Short Term Debt | 4.3M | 2.4M | 2.0M | 2.3M | 2.0M | 1.4M | |
Other Current Liab | 2.4M | 2.4M | 1.7M | 3.5M | 3.7M | 3.9M | |
Cash | 144.3K | 4.3M | 5.8M | 85.3K | 716.8K | 839.1K | |
Cash And Short Term Investments | 144.3K | 4.3M | 5.9M | 161.1K | 796.1K | 855.2K | |
Common Stock | 19.5K | 24.4K | 28.9K | 32.9K | 7.9K | 7.5K | |
Net Receivables | 640.5K | 999.4K | 1.7M | 1.4M | 759.6K | 625.0K | |
Other Current Assets | 570.4K | 1.7M | 1.9M | 150.2K | 101.1K | 96.0K | |
Non Current Assets Total | 6.0M | 5.4M | 4.1M | 6.9M | 13.3M | 14.0M | |
Non Currrent Assets Other | 179.5K | 164.8K | 160.5K | 1.3M | 1.4M | 1.5M | |
Common Stock Total Equity | 213.7K | 213.9K | 19.5K | 24.4K | 28.1K | 26.7K | |
Accumulated Other Comprehensive Income | 663.8K | 564.9K | 539.7K | 517.1K | 516.4K | 396.8K | |
Net Tangible Assets | (5.7M) | (151.0K) | 3.4M | 8.8M | 10.2M | 10.7M | |
Other Assets | 1.4M | 1.6M | 2.0M | 1.1M | 1.3M | 1.4M | |
Short Long Term Debt | 4.0M | 2.1M | 1.8M | 1.9M | 1.5M | 2.0M | |
Other Liab | 27.5K | 2.9K | 19.3K | 10.6K | 12.2K | 11.0K | |
Short Term Investments | 3.4M | 1.2M | 108.1K | 75.8K | 79.3K | 75.3K | |
Long Term Investments | 3.4M | 1.2M | 932.8K | 842.1K | 2.5M | 1.8M | |
Property Plant Equipment | 510.1K | 1.0M | 2.3M | 2.0M | 2.3M | 2.4M | |
Net Invested Capital | 3.9M | 8.1M | 10.7M | 5.0M | 9.9M | 10.3M | |
Net Working Capital | (5.9M) | 1.3M | 5.9M | (2.8M) | (4.3M) | (4.1M) | |
Capital Stock | 19.5K | 24.4K | 28.9K | 32.9K | 7.9K | 7.5K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for ABVC Stock analysis
When running ABVC Biopharma's price analysis, check to measure ABVC Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ABVC Biopharma is operating at the current time. Most of ABVC Biopharma's value examination focuses on studying past and present price action to predict the probability of ABVC Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ABVC Biopharma's price. Additionally, you may evaluate how the addition of ABVC Biopharma to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Money Managers Screen money managers from public funds and ETFs managed around the world |
Is ABVC Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ABVC Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.43) | Revenue Per Share 0.035 | Quarterly Revenue Growth (1.00) | Return On Assets (0.43) | Return On Equity (1.92) |
The market value of ABVC Biopharma is measured differently than its book value, which is the value of ABVC that is recorded on the company's balance sheet. Investors also form their own opinion of ABVC Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ABVC Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ABVC Biopharma's market value can be influenced by many factors that don't directly affect ABVC Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ABVC Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ABVC Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ABVC Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.